These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15332589)

  • 41. [The role of angiotensin II receptors in the pathogenesis of cardiovascular diseases].
    Lehtonen J
    Duodecim; 1999; 115(13):1395-400. PubMed ID: 11912625
    [No Abstract]   [Full Text] [Related]  

  • 42. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Protective strategy of vascular endothelium].
    Tang CS; Lin L
    Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(2):89-90. PubMed ID: 12817574
    [No Abstract]   [Full Text] [Related]  

  • 45. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level.
    Jiang JL; Zhu HQ; Chen Z; Xu HY; Li YJ
    Int J Cardiol; 2005 May; 101(1):153-5. PubMed ID: 15860402
    [No Abstract]   [Full Text] [Related]  

  • 48. Chymase: a new pharmacologic target in cardiovascular disease.
    Bacani C; Frishman WH
    Cardiol Rev; 2006; 14(4):187-93. PubMed ID: 16788331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How do recent developments affect the angiotensin receptor blockers as a class?
    Cardiovasc J Afr; 2009; 20(2):145. PubMed ID: 19421654
    [No Abstract]   [Full Text] [Related]  

  • 51. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme.
    Hirota T; Ohki K; Kawagishi R; Kajimoto Y; Mizuno S; Nakamura Y; Kitakaze M
    Hypertens Res; 2007 Jun; 30(6):489-96. PubMed ID: 17664851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldosterone blockade in cardiovascular disease.
    Struthers AD
    Heart; 2004 Oct; 90(10):1229-34. PubMed ID: 15367532
    [No Abstract]   [Full Text] [Related]  

  • 54. Restenosis: another "dysfunction" of the endothelium.
    Lerman A
    Circulation; 2005 Jan; 111(1):8-10. PubMed ID: 15630036
    [No Abstract]   [Full Text] [Related]  

  • 55. Endothelial dysfunction--can we improve it?
    Wojtczak A
    Acta Pol Pharm; 2004 Dec; 61 Suppl():32-4. PubMed ID: 15909932
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis.
    Takai S; Jin D; Muramatsu M; Okamoto Y; Miyazaki M
    Eur J Pharmacol; 2004 Oct; 501(1-3):1-8. PubMed ID: 15464056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Possibilities of ramipril in primary and secondary prevention of cardiovascular diseases].
    Tkacheva ON; Sharashkina NV
    Kardiologiia; 2010; 50(8):63-6. PubMed ID: 21105331
    [No Abstract]   [Full Text] [Related]  

  • 58. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
    Fiebeler A; Luft FC
    Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
    [No Abstract]   [Full Text] [Related]  

  • 59. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 60. Influence of protein-restricted diets on proteinuria and endothelial dysfunction.
    Ecder T
    J Ren Nutr; 2009 Sep; 19(5 Suppl):S13-4. PubMed ID: 19712868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.